October 16, 2021

AIIMS Delhi to commence screening children from 6-12 years for Covaxin clinical trials

Spread the love

The All India Institute of Medical Sciences (AIIMS), New Delhi will on Tuesday commence the screening of children from the age group of 6 – 12 years for the clinical trials for the Hyderabad-based Bharat Biotech indigenously prepared Covid-19 vaccine Covaxin. “The selection process for the clinical trial of Covaxin among children in the age group of 6-12 years will begin from Tuesday,” said Dr. Sanjay Rai, Professor, Centre for Community Medicine at AIIMS Delhi as quoted to PTI on Monday.

The selection for clinical trials for the 12-18 years is completed and children in the age group have been given a single dose of the vaccine. After the recruitment of the children is complete, AIIMS, New Delhi will accordingly commence with the clinical trials.

Before Delhi, the AIIMS Patna branch already began with clinical trials on children of Covaxin for 12-18 years scheduled from June 3.

Director of AIIMS Patna, Dr. Prabhat Kumar Singh said, “After these trials, the age group will be 6-12 years and then 2-6 years but now we have started trials in the age group of 12-18 years,” further adding that in the previous week 54 children enrolled for the trials from which 16 of them were from 12-18 years of age.

Earlier on May 12, the Drugs Controller General of India (DCGI) had granted approval for conducting the second and the third phase of the clinical trial of Covaxin in children from 2-18 years group. PTI cited the trials will be conducted in three parts, comprising of 175 volunteers each in 12-18 years, 6-12 years and 2-6 years age groups.

The vaccine will be given through the intramuscular route in two doses on day 0 and after 28 days which will review the safety, reactogenicity, and immunogenicity of the Covid-19 vaccine among the children revealed PTI.

error: Content is protected !!